Drug intelligence / Profile preview

temelimab

Development stage: Phase 2
Lead developer: GeNeuro
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Temelimab is a first-in-class, humanized IgG4 monoclonal antibody developed to target the envelope protein of the human endogenous retrovirus type W (HERV-W Env), also known as MSRV-Env or syncytin-1. This viral protein is implicated in the pathogenesis of multiple sclerosis (MS) and other autoimmune diseases. By neutralizing HERV-W Env, temelimab aims to reduce neuroinflammation and neurodegeneration associated with these conditions. The drug has demonstrated safety and tolerability in phase I and II clinical trials for MS, with additional development in post-acute COVID-19 syndrome and previous investigation in type 1 diabetes mellitus[2][5][8]. Temelimab is being developed by GeNeuro.

Other names: temelimab

Targets

HERV-W Env (Human endogenous retrovirus W envelope protein)

Beyond the preview

Go deeper on temelimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on temelimab.

Explore the full profile